# Safety and Efficacy Study of Novel Gene Therapy ZM-01 for X-linked Retinoschisis Patients

> **NCT06066008** · EARLY_PHASE1 · COMPLETED · sponsor: **Zhongmou Therapeutics** · enrollment: 2 (actual)

## Conditions studied

- X-linked Retinoschisis

## Interventions

- **DRUG:** ZM-01-L
- **DRUG:** ZM-01-H

## Key facts

- **NCT ID:** NCT06066008
- **Lead sponsor:** Zhongmou Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-25
- **Primary completion:** 2023-10-31
- **Final completion:** 2026-01-31
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2026-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06066008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06066008, "Safety and Efficacy Study of Novel Gene Therapy ZM-01 for X-linked Retinoschisis Patients". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06066008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*